The Pharma Data

NOVEMBER 30, 2020

Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today provided an update on its COVID-19 vaccine program. NVX-CoV2373 contains purified protein antigen and can neither replicate, nor can it cause COVID-19. GAITHERSBURG, Md., and Australia.

Clinical Development 52

Clinical Development Vaccination Vaccine Development 52

Pharmaceutical Technology

JULY 29, 2022

Pfizer (New York, New York) and Moderna’s (Cambridge, Massachusetts) Omicron-specific Covid-19 vaccines are in late-stage development, have demonstrated good efficacy against the variant and will likely be available to the public later this year to provide an additional booster and increase demand for injectable manufacturing.

Manufacturing 130

Manufacturing Vaccination Vaccine Packaging 130

The Pharma Data

DECEMBER 29, 2020

As in earlier outpatient trial, immune status when patients entered the trial was a strong predictor of viral load and clinical outcomes. First antibody therapy to demonstrate anti-viral effect in patients hospitalized with COVID-19. Regeneron Pharmaceuticals, Inc. futility analysis). The results passed the futility analysis (p<0.3

Antibody 52

Antibody Trials Production Clinical Trials 52

The Pharma Data

AUGUST 15, 2021

Even as several safe and effective COVID-19 vaccines are being administered to people worldwide, scientists are still hard at work developing different vaccine strategies that could provide even stronger or longer-lasting immunity against SARS-CoV-2 and its variants.

Protein 52

Protein Vaccination Vaccine Antibody 52

The Pharma Data

DECEMBER 16, 2020

Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced an Advance Purchase Agreement with the government of New Zealand for the purchase of 10.7 NVX-CoV2373 contains purified protein antigen and can neither replicate, nor can it cause COVID-19.

Protein 52

Protein Vaccination Vaccine Immune Response 52

pharmaphorum

MAY 11, 2021

The technology is designed to replace antibodies, which have become standard therapy in many diseases but are complicated and expensive to manufacture. Unlike the strips of mRNA used to create Moderna’s COVID-19 vaccine, eRNA runs in a circle and has been specially modified to allow the body to read the code it contains.

RNA 98

RNA Drugs Protein Immune Response 98

The Pharma Data

DECEMBER 17, 2020

NASDAQ: REGN ) today announced that the New England Journal of Medicine (NEJM) has published initial clinical data from an ongoing seamless Phase 1/2/3 trial of the antibody cocktail casirivimab and imdevimab in non-hospitalized patients with COVID-19. TARRYTOWN, N.Y. , 17, 2020 /PRNewswire/ — Regeneron Pharmaceuticals, Inc.

Antibody 52

Antibody Medicine Production Trials 52

XTalks

APRIL 26, 2021

After years of disappointing malaria vaccine trials, a malaria shot developed by researchers at the Jenner Institute at the University of Oxford has demonstrated an unprecedentedly high efficacy of 77 percent, and may be the magic bullet the world has been waiting for against the deadly disease. Malaria Vaccine Phase II Trial.

Vaccination 105

Vaccination Vaccine Immune Response Trials 105

XTalks

MAY 4, 2023

When a person with celiac disease eats something that contains gluten, their immune system attacks their small intestine, damaging the lining and interfering with the absorption of nutrients from food. A blood test can detect antibodies to gluten, but a definitive diagnosis requires a biopsy of the small intestine.

Clinical Trials 98

Clinical Trials Clinical Trials Trials Immune Response 98

The Pharma Data

NOVEMBER 9, 2020

(Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that the U.S. Currently in late-phase clinical development, NVXCoV2373 is a stable, prefusion protein made using Novavax’ nanoparticle technology and includes its proprietary MatrixM adjuvant. “The

Vaccination 52

Vaccination Vaccine Clinical Trials Clinical Trials 52

XTalks

MAY 7, 2021

Glenn, president of research and development at Novavax, in a news release. “It It also demonstrates that ongoing evaluation of COVID-19 vaccine efficacy against SARS-CoV-2 variants is urgently needed to inform vaccine development and use.”. Despite the less then stellar efficacy posted against B.1.351

Protein 97

Protein Vaccination Vaccine Trials 97

The Pharma Data

OCTOBER 28, 2020

NASDAQ: REGN) today announced positive, prospective results from an ongoing Phase 2/3 seamless trial in the COVID-19 outpatient setting showing its investigational antibody cocktail, REGN-COV2, met the primary and key secondary endpoints. Senior Vice President and Head of Global Clinical Development at Regeneron. Yancopoulos , M.D.,

Antibody 40

Antibody Trials Production Clinical Trials 40

pharmaphorum

AUGUST 16, 2020

The European Commission has placed its first advance order for a coronavirus vaccine, snapping up 300 million doses of AstraZeneca’s ChAdOx1 candidate developed by the University of Oxford, with an option on another 100 million. The EU says its advance purchase order will finance part of the upfront costs of developing the vaccine.

Vaccination 111

Vaccination Vaccine Immune Response Trials 111

The Pharma Data

DECEMBER 8, 2020

The COVID-19 vaccine under development by China’s Sinopharm is showing efficacy of 86%, health authorities from the United Arab Emirates reported this morning. In August, the company reported the vaccine candidate triggered antibody-based immune responses in early and mid-stage trials.

Vaccination 52

Vaccination Vaccine Immune Response Antibody 52

The Pharma Data

OCTOBER 14, 2020

Food and Drug Administration (FDA) to begin a Phase I clinical trial of hAd5-COVID-19, the company’s novel COVID-19 vaccine candidate that targets both the inner nucleocapsid (N), engineered to activate T cells, and outer spike (S) protein, engineered to activate antibodies against the coronavirus (SARS-CoV-2).

Antibody 52

Antibody Vaccination Vaccine Trials 52

pharmaphorum

SEPTEMBER 2, 2021

Anna Biosciences’ Dr Anthony Rullo discusses the drug development company’s immunotherapy platform. Over the last 30 years, we have seen dramatic improvements in patient outcomes due to the emergence of biologics – particularly monoclonal antibodies – as therapies for a wide variety of diseases and infections.

Antibody 52

Antibody Protein Immune Response Vaccination 52

XTalks

MAY 1, 2023

Tofersen was discovered by Ionis Pharmaceuticals, and Biogen licensed tofersen from Ionis under a collaborative development and license agreement. While the exact causes of ALS are not fully understood, research suggests that the mutation of SOD1 may be linked to the development of the condition. What is SOD1 -ALS?

FDA Approval 89

FDA Approval Gene Genetics Protein 89

The Pharma Data

DECEMBER 13, 2020

SYNB1891 is an investigational drug for the intra-tumoral treatment of solid tumors and lymphoma, composed of an engineered Synthetic Biotic designed to activate the STING pathway in the tumor microenvironment in order to upregulate the patient’s immune response. Synlogic’s President and Chief Executive Officer.

Immune Response 40

Immune Response Engineer Clinical Trials Clinical Trials 40

The Pharma Data

DECEMBER 10, 2020

The vaccine targeted both the inner nucleocapsid (N) and the outer spike (S) proteins of the virus to maximize the immune response. The goal of targeting both S and N was to both activate virus-specific T cells and generate anti-SARS-CoV-2-neutralizing antibodies. hAd5-COVID-19 Oral Formulation.

Vaccination 52

Vaccination Vaccine Immune Response Protein 52

The Pharma Data

APRIL 22, 2023

The current COVID-19 vaccines are designed to trigger an antibody response to the SARS-CoV-2 spike protein, which is vulnerable to mutations that could make the vaccine less effective over time. These epitopes elicit an immune response from a broad selection of T cells, ensuring a sustained coverage of future variants.

Vaccination 40

Vaccination Vaccine Protein Antibody 40

The Pharma Data

APRIL 22, 2023

Paulson School of Engineering and Applied Sciences (SEAS) has developed a cell therapy as a strong alternative to existing small molecule and protein therapies that leverages myeloid cells, the very type of immune cells that cause the MS-triggering nerve inflammation in patients.

Immune Response 40

Immune Response Engineer In-Vivo Containment 40

Delveinsight

JANUARY 22, 2021

Thrombocytopenia pipeline possesses potential drugs in mid-stage developments to be approved shortly. Major key players involved in developing novel Thrombocytopenia treatment drugs market include UCB Biopharma , Principia Biopharma , Baxalta/Takeda , Argenx , etc. Similar is the picture of the Thrombocytopenia Drugs Market.

Marketing 65

Marketing Drugs Antibody Compliance 65

Pfizer

FEBRUARY 16, 2023

2-4 About VLA15 VLA15 is the only Lyme disease vaccine candidate currently in clinical development. VLA15 has demonstrated a strong immune response and satisfactory safety profile in pre-clinical and clinical studies so far. Pfizer Disclosure Notice The information contained in this release is as of February 17, 2023.

Clinical Trials 76

Clinical Trials Clinical Trials Vaccination Vaccine 76

The Pharma Data

OCTOBER 21, 2020

Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases, today announced that the U.S. The clearance of the IND for ADI-001 by the FDA is a significant milestone in the development of CAR ?? MENLO PARK, Calif. and BOSTON, Oct. About ADI-001.

Immune Response 40

Immune Response Engineer Clinical Trials Clinical Trials 40

The Pharma Data

OCTOBER 19, 2020

Immune responses following vaccination with PNEUMOVAX 23 (month 13) were comparable in both vaccination groups for the 15 serotypes in V114. Results from both studies are based on opsonophagocytic activity (OPA) responses – a measure of vaccine-induced functional antibodies. About PNEU-PATH.

Vaccination 52

Vaccination Vaccine Immune Response Containment 52

The Pharma Data

MARCH 8, 2021

inhibition,” said John Tsai, MD, Head of Global Drug Development and Chief Medical Officer at Novartis. Canakinumab is a human monoclonal antibody that binds with high affinity and selectivity to human interleukin-1beta (IL-1?) Novartis is committed to developing best-in-class treatments for lung cancer patients around the world.

Trials 52

Trials Immune Response Clinical Trials Clinical Trials 52

Drug Discovery World

OCTOBER 21, 2022

The advance could mean that future development of anti-cancer therapies won’t require the use of animal models. Triple-negative breast cancer cells can develop resistance to the chemotherapy drug doxorubicin. In a scientific first, researchers at Penn State successfully 3D bioprinted breast cancer tumours and treated them.

In-Vivo 52

In-Vivo Research Drugs Engineer 52

The Pharma Data

JANUARY 31, 2021

. The Coalition for Epidemic Preparedness Innovations (CEPI) continues to support Clover’s COVID-19 vaccine candidate and will fund its development through licensure. EMERYVILLE, Calif. and CHENGDU, China , Feb. EMERYVILLE, Calif. and CHENGDU, China , Feb. EMERYVILLE, Calif. and CHENGDU, China , Feb.

Vaccination 52

Vaccination Vaccine Trials Protein 52

XTalks

AUGUST 17, 2020

Immunotherapy continues to be a burgeoning field, with immune-based therapies being among the leading treatments being developed in oncology and autoimmunity. Monoclonal antibodies : these are antibodies that are designed to bind to specific targets on cells. Immune system modulators (i.e.

Protein 98

Protein Engineer Immune Response In-Vivo 98

The Pharma Data

DECEMBER 23, 2020

Stanley Plotkin , Professor Emeritus at The Wistar Institute, said, “INOVIO’s DNA vaccine appeared to be quite safe with few significant reactions but yet induced both antibody and T cell responses to SARS-CoV-2.” mg dose group and 84% demonstrating neutralizing antibodies in the 2.0 mg and 2.0 The 1.0

DNA 40

DNA Vaccination Vaccine Immune Response 40

The Pharma Data

AUGUST 15, 2021

About TICOVAC (Tick-borne encephalitis vaccine) Pfizer’s TBE vaccine, marketed under the brand names FSME-Immun ® and TicoVac in Europe, and TICOVAC in the U.S., is developed using a master ‘seed’ virus that is similar to the TBE virus found in nature. TICOVAC should not be given to anyone with a severe allergic reaction (e.g.

FDA Approval 52

FDA Approval Vaccination Vaccine Licensing 52

The Pharma Data

NOVEMBER 10, 2020

First Ever Study with take-home capsules of Foralumab , a Fully Human Anti-CD3 Monoclonal Antibody. We’re excited to be collaborating with Tiziana to support the development of a novel, oral therapy that could provide Crohn’s patients with another option in their repertoire of treatments to combat this devastating disease.”.

Life Science 40

Life Science Clinical Trials Clinical Trials Trials 40

The Pharma Data

NOVEMBER 17, 2020

Mymetics continues to progress its Covid-19 vaccine development plan based on its virosome-vaccine platform. Since April 2020, Mymetics’ goal is to develop a safe and highly effective virosome-based Covid-19 vaccine that can be easily administered to all age groups, particularly to immune compromised and elderly populations.

Vaccination 40

Vaccination Vaccine Containment Immune Response 40

The Pharma Data

AUGUST 20, 2020

T cell immune responses elicited by BNT162b2 are being evaluated in the German study and the companies expect to submit the data for peer review and potential publication. Senior Vice President and Head of Vaccine Research & Development, Pfizer. “We This press release features multimedia. View the full release here: [link].

Vaccination 52

Vaccination Vaccine Clinical Trials Clinical Trials 52

The Pharma Data

MARCH 16, 2021

1.351 carries another spike mutation E484K, which appears to evade the body’s immune response, possibly diminishing vaccine efficacy. 1 has been circulating in the Amazon region as of late 2020 and is thought to evade immunity generated after infection by other variants. 2,3 Another variant, B.1.351, 4 Variant P.1,

Antibody 52

Antibody Clinical Trials Clinical Trials Vaccination 52

The Pharma Data

SEPTEMBER 8, 2020

Nine CEOs sign historic pledge to continue to make the safety and well-being of vaccinated individuals the top priority in development of the first COVID-19 vaccines. FDA has established clear guidance for the development of COVID-19 vaccines and clear criteria for their potential authorization or approval in the US.

Vaccination 52

Vaccination Vaccine Containment Clinical Trials 52

The Pharma Data

SEPTEMBER 9, 2020

We would like to thank the European Commission for its commitment and confidence in our development efforts,” said Albert Bourla, Chairman and CEO, Pfizer. “We Our aim is to develop a safe and effective vaccine to contribute to bringing this pandemic to an end in Europe and across the world. CEO and Co-founder of BioNTech.

Vaccination 52

Vaccination Vaccine Clinical Trials Clinical Trials 52